This report was sent to Briefing.com subscribers earlier today.
Research calls posted earlier this morning are available here.
Upgrades:
> Acushnet (GOLF) upgraded to Buy from Neutral at Tigress Financial; tgt raised to $62
> argenx (ARGX) upgraded to Outperform from Neutral at Robert W. Baird; tgt $460
> Dell (DELL) upgraded to Outperform from Neutral at KGI Securities; tgt $47.50
> Freeport-McMoRan (FCX) upgraded to Sector Outperform from Sector Perform at Scotiabank; tgt raised to $50
> LexinFintech (LX) upgraded to Buy from Neutral at Citigroup; tgt raised to $3.60
> Pinnacle West (PNW) upgraded to Outperform from Neutral at Credit Suisse; tgt raised to $80
> Portland Gen Elec (POR) upgraded to Buy from Neutral at BofA Securities; tgt raised to $52
> Roku (ROKU) upgraded to Peer Perform from Underperform at Wolfe Research
> Tricon Residential (TCN) upgraded to Outperform from Peer Perform at Wolfe Research; tgt $9.25
> Unum Group (UNM) upgraded to Outperform from Mkt Perform at Keefe Bruyette; tgt raised to $52
Downgrades:
> Hancock Whitney (HWC) downgraded to Mkt Perform from Outperform at Keefe Bruyette; tgt lowered to $50
> Hancock Whitney (HWC) downgraded to Neutral from Buy at Janney; tgt $44.50
> Mid-America Aptmt (MAA) downgraded to Sector Perform from Sector Outperform at Scotiabank
> nCino (NCNO) downgraded to Neutral from Overweight at Piper Sandler; tgt lowered to $22
> Oportun Financial (OPRT) downgraded to Mkt Perform from Outperform at Keefe Bruyette; tgt lowered to $4
> Red Electrica (RDEIY) downgraded to Sector Perform from Outperform at RBC Capital Mkts
> Telefonica Deutschland (TELDF) downgraded to Neutral from Outperform at Credit Suisse
Others:
> Dick’s Sporting Goods (DKS) initiated with a Hold at Jefferies; tgt $155
> Durect (DRRX) initiated with a Buy at Jones Trading; tgt $37
> Encompass Health (EHC) initiated with an Equal Weight at Barclays; tgt $57
> Hibbett (HIBB) initiated with a Hold at Jefferies; tgt $69
> Lilium GmbH (LILM) initiated with a Neutral at Citigroup; tgt $1
> Trevi Therapeutics (TRVI) initiated with a Buy at Jones Trading; tgt $7
Smart Investors Are Quietly Loading Up on These “Dividend Legends” (Sponsored)
If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you.
Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
